Research Article

Treatment of Punctate Inner Choroidopathy with Choroidal Neovascularization Using Corticosteroid and Intravitreal Ranibizumab

Wei Wu,1 Shiying Li,1 Haiwei Xu,1 Yong Liu,1 Yi Wang,1 Timothy Y. Y. Lai,2 and Zheng Qin Yin1

1Southwest Hospital/Southwest Eye Hospital, Third Military Medical University (Army Medical University), Chongqing, China
2Department of Ophthalmology & Visual Sciences, Chinese University of Hong Kong, Hong Kong

Correspondence should be addressed to Shiying Li; shiying_li@126.com

Received 1 April 2018; Revised 30 July 2018; Accepted 14 August 2018; Published 13 September 2018

1. Background

Punctate inner choroidopathy (PIC) is a specific form of posterior uveitis, firstly described by Watzke and colleagues in 1984 [1]. The disease most commonly affects young, myopic women and is characterized by multifocal, well-circumscribed, yellow-white choroidal lesions at the posterior pole of the retina, without anterior or vitreous inflammation. Subfoveal lesions can result in symptoms including blurred vision, scotoma, metamorphopsia, and photopsia [2, 3]. PIC does not usually cause severe visual loss until development of choroidal neovascularization (CNV), but CNV can develop in up to 70% of patients with PIC [2, 4]. Considering that PIC is a kind of ocular inflammatory disorder, corticosteroid is recommended to reduce inflammation. For PIC patients without CNV, oral corticosteroid may help to achieve more rapid visual improvement although spontaneous resolution of the lesions can occur in many cases without treatment [5]. However, there is no consensus on the optimal treatment for PIC with CNV. A number of treatment modalities have been described, including thermal focal laser photocoagulation, surgical CNV extraction, and verteporfin photodynamic therapy (vPDT). However, these have demonstrated limited visual benefit, due to high rates of CNV recurrence, or irreversible damage to the retinal pigment epithelium (RPE) [6, 7].
More recently, antivascular endothelial growth factor (anti-VEGF) agents, such as ranibizumab, bevacizumab, and conbercept, have been used to treat CNV secondary to PIC, and they have appeared to be safe and effective [8–13]. We therefore hypothesized that the combination of oral corticosteroid and intravitreal ranibizumab could both reduce inflammation in PIC and treat secondary CNV. Here, we retrospectively studied 24 eyes, in 22 patients suffering from PIC with CNV, and compared combined oral corticosteroid-ranibizumab therapy with intravitreal ranibizumab monotherapy.

2. Methods

2.1. Study Design. We retrospectively studied the clinical records of 22 patients suffering from PIC with secondary CNV who attended the Southwest Eye Hospital, Chongqing, China, from June 2009 to September 2017. This study was performed in accordance with the tenets of the Declaration of Helsinki and was approved by the ethics committee of Southwest Hospital, Third Military Medical University. Consent was obtained from all patients for use of their clinical data for this study.

A diagnosis of PIC was made by two experienced retinal specialists, independently, on the basis of clinical examination, fluorescein angiography (FA) and/or indocyanine green angiography (ICGA), fundus autofluorescence (FAF), and optical coherence tomography (OCT). PIC lesions were classified into five stages, according to the method by Zhang and colleagues [2, 14]. In order to exclude other causes of posterior uveitis, all patients underwent laboratory workup and imaging studies including chest X-ray, detection of systemic infections such as toxoplasmosis, syphilis, varicella-zoster, and herpes, and antibody against mycobacterium tuberculosis. Other exclusion criteria for the current study included patients with follow-up of less than three months and patients with CNV secondary to other causes (such as age-related macular degeneration, polypoidal choroidal vasculopathy, pathologic myopia, and angiod streaks).

Following diagnosis of PIC with CNV, all patients were advised to receive combination therapy with oral corticosteroid and intravitreal ranibizumab, and 8 patients (2 with bilateral disease) proceeded with this regime. Fourteen patients refused corticosteroid due to potential side effects and were therefore only given ranibizumab monotherapy. This provided us with a combination corticosteroid-ranibizumab treatment group (n = 10 eyes) and a ranibizumab monotherapy group (n = 14 eyes), for retrospective comparison of outcome.

Intravitreal ranibizumab monotherapy was performed using a single intravitreal injection of 0.5 mg ranibizumab (Lucentis, Novartis, Basel, Switzerland) in 0.05 mL water for injections, followed by as needed injections, as judged necessary by the responsible ophthalmologist. The corticosteroid-ranibizumab group additionally received oral prednisolone (1 mg/kg per day initially, then weaned by 10 mg every 14 days). To minimize the potential side effects of corticosteroids, patients were treated with oral prednisone for no more than 3 months.

Follow-up OCT and FAF were performed after treatment to assess the activity and progression of PIC and to determine further treatment. When necessary, additional FA and/or ICGA were performed to determine the activity of PIC and CNV during follow-up. Retreatment with ranibizumab was administered in cases with persistent or recurrent intraretinal edema, or subretinal fluid demonstrated by OCT, and/or hemorrhage from CNV demonstrated by FA.

2.2. Statistical Analysis. For statistical analysis, Snellen best-corrected visual acuity (BCVA) was converted to the logarithm of the minimum angle of resolution (logMAR) equivalents. We used the unpaired (independent) two-sample t-test to compare the means between the two groups and the Mann–Whitney U test where parametric test assumptions were not satisfied. For within-group comparisons (e.g., between two time-points) we used the paired t-test. A P value of < 0.05 was considered to be statistically significant.

3. Results

3.1. Patient Demographics. Twenty-four eyes of 22 patients (6 male and 16 female) were included in the study. Twenty patients (90.9%) had unilateral disease and 2 (9.1%) cases (both of whom were in the corticosteroid-ranibizumab group) had bilateral PIC. The mean ± standard deviation (SD) age of the patients at presentation was 38.3 ± 11.7 years (range, 22–65 years). Notably, the mean ± SD age of the patients in ranibizumab monotherapy group (42.9 ± 11.4) was significantly higher than that in the corticosteroid-ranibizumab group (30.0 ± 8.0) (P = 0.006, unpaired t-test). Of the 24 eyes, 23 (95.8%) eyes had myopia of −2.25 D or more. Fourteen eyes received ranibizumab monotherapy and 10 eyes received combined corticosteroid and ranibizumab therapy (Table 1). The mean (± SD) number of ranibizumab injections given in the corticosteroid-ranibizumab group (1.9 ± 1.0 injections; range, 1–3) was less than that in the ranibizumab monotherapy group (3 ± 1.7 injections; range, 1–7), although this difference was not significant (P = 0.102, Mann–Whitney U test). Mean follow-up duration was 24 months (range, 3–52 months) across all patients, and there was no difference between the ranibizumab monotherapy group (23.4 ± 16.0 months) and the corticosteroid-ranibizumab group (24.5 ± 10.0) (P = 0.844, unpaired t-test).

3.2. Visual Acuity and Recurrence of CNV. Table 1 shows the treatment outcomes of all 24 eyes. In the ranibizumab monotherapy group (14 eyes), the mean (± SD) logMAR BCVA at baseline was 0.68 ± 0.46. At the last follow-up, the mean logMAR BCVA improved significantly to 0.33 ± 0.39 (P = 0.02, paired t-test). In the corticosteroid-ranibizumab therapy group (10 eyes), the mean (± SD) logMAR BCVA improved significantly from 0.82 ± 0.52 at baseline to 0.22 ± 0.23 at the last visit (P = 0.01, paired t-test). Comparing the two groups, the initial mean BCVA was not significantly different (P = 0.378, Mann–Whitney U test). In addition, the mean improvement (± SD) in logMAR BCVA in the corticosteroid-ranibizumab group (0.61 ± 0.43) was higher.

BioMed Research International
Table 1: Patient characteristics and responses to treatment.

|                                | Intravitreal ranibizumab monotherapy (n = 14 eyes) | Combined corticosteroid and ranibizumab (n = 10 eyes) | P value |
|--------------------------------|-----------------------------------------------|---------------------------------------------------|---------|
| Mean age                       | 42.9                                          | 30.0                                              | 0.006   |
| Mean follow-up                 | 23.3 months                                   | 24.5 months                                       | 0.844   |
| Initial BCVA                   | 0.68 logMAR                                   | 0.82 logMAR                                       | 0.378   |
| Final BCVA                     | 0.34 logMAR                                   | 0.22 logMAR                                       | 0.174   |
| Change of BCVA                 | -0.34 logMAR                                  | -0.61 logMAR                                      |         |
| Mean intravitreal injections given | 3.0                                          | 1.9                                               | 0.102   |
| Recurrent CNV (eyes)           | 8 (57.1%)                                     | 0 (0%)                                            |         |
| Improved or stable BCVA (eyes) | 13 (92.9%)                                    | 10 (100%)                                         |         |
| Reduced lesions (eyes)         | 0 (0%)                                        | 2 (20%)                                           |         |
| Stable lesions (eyes)          | 8 (57.2%)                                     | 6 (60%)                                           |         |
| New lesions (eyes)             | 6 (42.8%)                                     | 2 (20%)                                           |         |

Improved or stable BCVA means that BCVA of the patient kept stable (less than 0.1 in change) or was improved to more than 0.1 after the treatment.

than that seen in the ranibizumab monotherapy group (0.34 ± 0.46), although the difference between the two groups was not significant (P = 0.174, unpaired t-test). However, three months after the first ranibizumab treatment, 8 eyes (57.1%) developed recurrence of CNV in the ranibizumab monotherapy group (e.g., Figure 1), whereas no eyes developed recurrence in the corticosteroid-ranibizumab group.

3.3. Anatomical Outcome of PIC Lesions. We next used the number of PIC lesions as an outcome measure. PIC lesions in the 24 eyes included in this study were all classified as being stage III or IV. Specifically, fundal examination showed yellow-white creamy spots (e.g., Figure 2(a)). An even larger number of hypofluorescent spots were typically evident with FAF (e.g., Figure 2(b)). FA typically showed multifocal hyperfluorescent spots (e.g., Figure 2(c)), which appeared at ICGA as areolar hyperfluorescence around central dark spot (e.g., Figure 2(d)). OCT typically revealed subfoveal CNV, with reflectivity defects throughout the RPE (e.g., Figure 2(e)). After combined corticosteroid-ranibizumab therapy, both CNV and PIC lesions typically improved (e.g., Figures 2(f)–2(j)). Furthermore, in 2 eyes (20%), the number of PIC lesions was reduced; in 6 eyes (60%), the number was stable; and only 2 (20%) eyes developed new lesions. By comparison, after ranibizumab monotherapy, none of the eyes (0%) had reduced numbers of lesions, 8 eyes (57.2%) had a stable number of lesions, and 6 eyes (42.8%) developed new lesions.

3.4. Adverse Events. Following treatment, we did not observe any instances of endophthalmitis, retinal detachment, glaucoma, any other serious ocular adverse events, or systemic adverse events.

4. Discussion

Patients with PIC generally have good visual prognosis unless the lesions are subfoveal or secondary CNV develops [1, 4, 16]. PIC can be considered as one of the clinical phenotypes seen among patients with multifocal choroiditis, and immunosuppressive therapy might therefore have a role in the treatment of PIC [17, 18]. Subfoveal CNV can result in significant visual loss, due to irreversible damage to the neurosensory retina and RPE. Treatment options for CNV secondary to PIC include thermal laser photocoagulation, submacular surgery, oral corticosteroid (or other immunomodulators), vPDT, and intravitreal anti-VEGF therapy [19]. Among these treatment options, vPDT and intravitreal anti-VEGF injection are currently the most widely used. Table 2 summarizes several studies on the treatment of CNV secondary to PIC. Whilst vPDT treatment has been shown to be beneficial for stabilizing and also improving vision in some patients with PIC and CNV, one-third of eyes have persistent poor visual acuity [15]. vPDT may also cause collateral damage to the retinal and RPE layers, so visual outcomes can be inconsistent [7].

VEGF has a pivotal role in the development of CNV, and anti-VEGF therapy has been shown to be safe and effective as a first-line treatment for CNV due to ocular inflammatory like PIC [11–13]. In a previous retrospective study of 10 eyes suffering from PIC with CNV, the authors report that intravitreal ranibizumab monotherapy improved or stabilized vision in 9 eyes, with a mean follow-up period of 12.5 months [11]. Here we report findings from 14 eyes receiving ranibizumab monotherapy, with a mean follow-up of 23.3 months, and have shown that, whilst anti-VEGF monotherapy did improve vision, 8 eyes (57.1%) developed recurrent CNV.

Because inflammation contributes to the development of PIC and secondary CNV, anti-inflammatory treatments play a key role in reducing or eradicating the stimulus that leads to CNV formation [6]. It is thought that corticosteroid can reduce development of CNV by inhibiting both VEGF [20, 21] and matrix metalloproteinases [22], thus providing both anti-inflammatory and antiangiogenic properties. However,
Figure 1: (a) Fundus photograph of the right eye of a 36-year-old female PIC patient at the initial presentation showing 5 yellow-white lesions of PIC and subfoveal hemorrhage. The logMAR BCVA at presentation was 0.52. (b) FAF showed well-defined hypoautofluorescence in the lesions. (c) OCT showed the presence of CNV and intraretinal fluid. (d-f) Fundus photograph, FAF, and OCT examination 3 months after 3 ranibizumab monthly intravitreal injections. The patient's CNV resolved and logMAR BCVA increased to 0.1. (g-i) Fundus photograph, FAF, and OCT examination 8 months later. Recurrent CNV was noted and logMAR BCVA decreased to 0.4.

Table 2: Comparison of studies on the treatment of CNV secondary to PIC.

| Study design | Coco et al. [15] | Peng et al. [12] | Fong et al. [6] | Menezo et al. [11] | Zhang et al. [8] | Our study |
|--------------|------------------|------------------|-----------------|--------------------|-----------------|-----------|
| No. of eyes  | Retrospective 8  | Prospective 16   | Prospective 5   | Retrospective 10   | Prospective 12  | Retrospective 24 |
| Treatment    | vPDT             | Conbercept       | vPDT+ Corticosteroid | Ranibizumab        | Bevacizumab     | Ranibizumab +/- Corticosteroid |
| Initial BCVA (logMAR) | 0.42             | 0.70             | 0.54            | 0.72               | 0.49            | Ranibizumab: 0.68; Ranibizumab+ Corticosteroid: 0.82 |
| Final BCVA (logMAR) | 0.51             | 0.44             | 0.39            | 0.37               | 0.23            | Ranibizumab: 0.34; Ranibizumab+ Corticosteroid: 0.22 |
| Mean follow-up (months) | 22.7             | 6                | 12              | 12.5               | 12              | Ranibizumab: 23.3; Ranibizumab+ Corticosteroid: 24.5 |
| Improved or stable BCVA (eyes) | 5 (62.5%)         | 16 (100%)        | 4 (80%)         | 9 (90%)            | 12 (100%)       | Ranibizumab: 13 (92.9%); Ranibizumab+ Corticosteroid: 10 (100%) |

Improved or stable BCVA means that BCVA of the patient kept stable (less than 0.1 in change) or was improved to more than 0.1 after the treatment.
Figure 2: (a) Fundus photograph of the right eye of a 28-year-old female patient with PIC and CNV at initial presentation, showing yellow-white choroidal lesions and subfoveal hemorrhage. The logMAR BCVA was 0.7. (b) FAF image showed clear hypofluorescence of the lesions. (c) Late-phase FA image detected hyperfluorescent lesions. (d) Late-phase ICGA image detected areolar hyperfluorescence surrounding central dark spots. (e) OCT image demonstrated the presence of CNV and intraretinal fluid. (f) Fundus photograph at 12 months after initiating combined oral corticosteroid and ranibizumab therapy. The logMAR BCVA increased to 0. (g) FAF image showed less hypofluorescent lesions posttreatment. Note an evident resolution of the lesions compared with the first visit (white arrows). (h) Late-phase FA image showed less hyperfluorescent lesions after treatment (white arrows). (i) Late-phase ICGA image showed dramatic resolution and shrinkage of hypofluorescent lesions posttreatment (black arrows). (j) OCT showed the resolution of the CNV and intraretinal fluid.

there is still debate about whether PIC associated with CNV should be treated with corticosteroid [23]. In our study, we therefore studied the benefit of combining oral prednisolone and intravitreal ranibizumab to treat PIC with CNV. None of the 10 eyes treated using this regime developed recurrent CNV. Patients receiving combined corticosteroid–anti-VEGF appeared to have greater improvement in vision and to require fewer intravitreal anti-VEGF injections compared with anti-VEGF monotherapy. However, these results were not statistically significant, and the retrospective, nonrandomized nature of this study means we cannot exclude the effect of biases and confounders. Consistent with our findings, previous small-scale case series (less than 3 patients) have reported that combining corticosteroid and anti-VEGF therapy should be considered as a management of CNV associated with PIC [24, 25]. In addition to corticosteroids, immunosuppressants have also been proposed for control of inflammatory CNV [26]. Considering the side effects, administration of corticosteroids and immunosuppressants should be based on the patients’ general and ocular conditions. Notably, combination of corticosteroids with immunosuppressive drugs (e.g., mycophenolate mofetil) is recommended for the CNV unresponsive to traditional immunosuppressants [27].

In our study, we also evaluated the potential therapeutic effects of corticosteroid on PIC itself. To thoroughly analyze the changes in PIC lesions, a dual FA/ICGA imaging is strongly encouraged [28]. As shown in Figure 2, both FA and ICGA image showed a dramatic resolution and shrinkage of PIC lesions after combined corticosteroid-ranibizumab therapy. Compared with the 14 eyes in the anti-VEGF monotherapy group, the 10 eyes which received combined therapy had better resolution of PIC lesions and developed fewer new lesions. This is consistent with a previous study, which has shown that oral corticosteroid promotes the resolution of PIC lesions [5].

5. Conclusions

Our results demonstrate that both corticosteroid-ranibizumab treatment and ranibizumab monotherapy can significantly improve the vision of PIC patients with CNV. Combined corticosteroid and intravitreal ranibizumab treatment appeared to reduce CNV recurrence and development of
new PIC lesions compared with ranibizumab monotherapy. Clearly the strength of these conclusions is limited by the retrospective nature of this study and the small sample size. Ideally, a prospective, randomized placebo-controlled trial would be performed, with a longer follow-up duration, to more conclusively determine the role of combined oral corticosteroid and anti-VEGF as first-line treatment for PIC with secondary CNV.

Abbreviations
PIC: Punctate inner choroidopathy
CNV: Choroidal neovascularization
vPDT: Verteporfin photodynamic therapy
RPE: Retinal pigment epithelium
VEGF: Vascular endothelial growth factor
FA: Fluorescein angiography
ICGA: Indocyanine green angiography
FAF: Fundus autofluorescence
OCT: Optical coherence tomography
BCVA: Best-corrected visual acuity
LogMAR: Logarithm of the minimum angle of resolution
SD: Standard deviation.

Data Availability
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethical Approval
Approval was obtained by the ethics committee of Southwest Hospital, Third Military Medical University. The study was adhered to the tenets of the Declaration of Helsinki.

Consent
In this study, we published the data from two typical patients, including the clinical findings and images. A written consent for publication was obtained from the patients.

Conflicts of Interest
The authors declare that there are no conflicts of interest.

Authors’ Contributions
Wei Wu and Shiying Li contributed to study design and data acquisition and analysis. Wei Wu drafted and revised the manuscript. Shiying Li and Timothy Y. Y. Lai critically revised the manuscript. Haiwei Xu, Yong Liu, Yi Wang, and Zheng Qin Yin acquire and analyze data. All authors read and approved the final manuscript.

Acknowledgments
This work was supported by the Third Military Medical University Translational Grant (2016zxh07), Chongqing Research Program of Basic Research and Frontier Technology (cstc2017jcyjAX0424), and Foundation for Southwest Hospital Clinical Medicine Young Talents (SWH2013QN08). We are grateful to Cheng Sun, Sha Li, Linbo He, and Bo Liu for supporting this study.

References
[1] R. C. Watzke, A. J. Packer, J. C. Folk, W. E. Benson, D. Burgess, and R. R. Ober, “Punctate inner choroidopathy,” American Journal of Ophthalmology, vol. 98, no. 5, pp. 572–584, 1984.
[2] X. Zhang, F. Wen, C. Zuo et al., “Clinical features of punctate inner choroidopathy in Chinese patients,” Retina, vol. 31, no. 8, pp. 1680–1691, 2011.
[3] R. W. Essex, J. Wong, S. Fraser-Bell et al., “Punctate inner choroidopathy: Clinical features and outcomes,” JAMA Ophthalmology, vol. 128, no. 8, pp. 982–987, 2010.
[4] A. T. Gerstenblith, J. E. Thorne, L. Sobrin et al., “Punctate inner choroidopathy: a survey analysis of 77 persons,” Ophthalmology, vol. 114, no. 6, pp. 1201.e1–1204.e4, 2007.
[5] J. Levy, M. Shneck, I. Klemperer, and T. Lifshitz, “Punctate inner choroidopathy: Resolution after oral steroid treatment and review of the literature,” Canadian Journal of Ophthalmology, vol. 40, no. 5, pp. 605–608, 2005.
[6] K. C. S. Fong, D. Thomas, K. Amin, D. Inzerillo, and S. E. Horgan, “Photodynamic therapy combined with systemic corticosteroids for choroidal neovascularisation secondary to punctate inner choroidopathy,” Eye, vol. 22, no. 4, pp. 528–533, 2008.
[7] L. Postelmans, B. Pasteels, P. Coquelet, H. El Ouardighi, C. Verougstraete, and U. Schmidt-Erfurth, “Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females,” American Journal of Ophthalmology, vol. 138, no. 5, pp. 803–808, 2004.
[8] H. Zhang, Z.-L. Liu, P. Sun, and F. Gu, “Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: Results of a 1-year prospective trial,” Retina, vol. 32, no. 6, pp. 1106–1113, 2012.
[9] H. Zhang, Z.-L. Liu, P. Sun, and F. Gu, “Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial,” American Journal of Ophthalmology, vol. 153, no. 2, pp. 300.e1–306.e1, 2012.
[10] K. S. Cornish, G. J. Williams, M. P. Gavin, and F. R. Imrie, “Visual and optical coherence tomography outcomes of intravitreal bevacizumab and ranibizumab in inflammatory choroidal neovascularization secondary to punctate inner choroidopathy,” European Journal of Ophthalmology, vol. 21, no. 4, pp. 440–445, 2011.
[11] V. Menezo, F. Cuthbertson, and S. M. Downes, “Positive response to intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to punctate inner choroidopathy,” Retina, vol. 30, no. 9, pp. 1400–1404, 2010.
[12] Y. Peng, X. Zhang, L. Mi et al., “Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy,” BMC Ophthalmology, vol. 17, no. 1, article no. 87, 2017.
[13] T.Y. Lai, G. Staurenghi, P. Lanzetta et al., “Efficacy and safety of ranibizumab for the treatment of choroidal neovascularization due to uncommon cause,” Retina, vol. 38, no. 8, pp. 1464–1477, 2018.

[14] X. Zhang, C. Zuo, M. Li, H. Chen, S. Huang, and F. Wen, “Spectral-domain optical coherence tomographic findings at each stage of punctate inner choroidopathy,” Ophthalmology, vol. 120, no. 12, pp. 2678–2683, 2013.

[15] R.M. Coco, C.E. De Souza, and M.R. Sanabria, “Photodynamic therapy for subfoveal and juxtapfoveal choroidal neovascularization associated with punctate inner choroidopathy,” Ocular Immunology and Inflammation, vol. 15, no. 1, pp. 27–29, 2007.

[16] T.G. Leung, A. Moradi, D. Liu et al., “Clinical features and incidence rate of ocular complications in punctate inner choroidopathy,” Retina, vol. 34, no. 8, pp. 1666–1674, 2014.

[17] R. Essex, J. Wong, L. Jampol, J. Dowler, and A. Bird, “Idiopathic multifocal choroiditis: A comment on present and past nomenclature,” Retina, vol. 33, no. 1, pp. 1–4, 2013.

[18] D. Ahnood, S. Madhusudhan, M.D. Tsaloumas, N.K. Waheed, P.A. Keane, and A.K. Denniston, “Punctate inner choroidopathy: A review,” Survey of Ophthalmology, vol. 62, no. 2, pp. 113–126, 2017.

[19] J. Campos, A. Campos, S. Mendes, A. Neves, D. Beselga, and J.C. Sousa, “Punctate inner choroidopathy: a systematic review,” Med Hypothesis Discov Innov Ophthalmol, vol. 3, no. 3, pp. 76–82, 2014.

[20] M. Nauck, G. Karakiulakis, A.P. Perruchoud, E. Papakonstantinou, and M. Roth, “Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells,” European Journal of Pharmacology, vol. 341, no. 2-3, pp. 309–315, 1998.

[21] H. Itaya, T. Imaizumi, H. Yoshida, M. Koyama, S. Suzuki, and K. Satoh, “Expression of vascular endothelial growth factor in human monocyte/macrophages stimulated with lipopolysaccharide,” Thrombosis and Haemostasis, vol. 85, no. 1, pp. 171–176, 2001.

[22] T.A. Ciulla, J.D. Walker, D.S. Fong, and M.H. Criswell, “Corticosteroids in posterior segment disease: An update on new delivery systems and new indications,” Current Opinion in Ophthalmology, vol. 15, no. 3, pp. 211–220, 2004.

[23] R.L. Niederer, R. Gilbert, S.L. Lightman, and O. Tomkins-Netzer, “Risk Factors for Developing Choroidal Neovascular Membrane and Visual Loss in Punctate Inner Choroidopathy,” Ophthalmology, vol. 125, no. 2, pp. 288–294, 2018.

[24] B. Hoherberger, M. Rudolph, and A. Bergua, “Choroidal Neovascularization Associated with Punctate Inner Choroidopathy: Combination of Intravitreal Anti-VEGF and Systemic Immunosuppressive Therapy,” Case Reports in Ophthalmology, vol. 6, no. 3, pp. 385–389, 2015.

[25] K.T. Tsoukis, M. Nassr, B. Kapoor, V.E. Konidaris, S. Tyradellis, and T. Empealidis, “Long-term results of intravitreal bevacizumab and dexamethasone for the treatment of punctate inner choroidopathy associated with choroidal neovascularization: A case series,” SAGE Open Medical Case Reports, vol. 6, pp. 1–5, 2018.

[26] E. D’Ambrosio, P. Tortorella, and L. Iannetti, “Management of uveitis-related choroidal neovascularization: From the pathogenesis to the therapy,” Journal of Ophthalmology, vol. 2014, Article ID 430428, 6 pages, 2014.

[27] P. Neri, M. Manoni, C. Fortuna, M. Lettieri, C. Mariotti, and A. Giovannini, “Association of systemic steroids and mycophenolate mofetil as rescue therapy for uveitic choroidal neovascularization unresponsive to the traditional immunosuppressants: Interventional case series,” International Ophthalmology, vol. 30, no. 5, pp. 583–590, 2010.

[28] C.P. Herborg, P. Neri, A.A. El Asrar et al., “Is ICGA still relevant in inflammatory eye disorders? Why this question has to be dealt with separately from other eye conditions,” Retina, vol. 32, no. 9, pp. 1701–1703, 2012.